Testosterone, estradiol, and genistein supplementation could hinder the development of NASH through the reduction of SREBP1c and FAS gene transcription, the activation of PPARα and PPARδ expressions, and the suppression of PPARγ and STAT1. Here, PPARG is linked to metabolic dysfunction-associated steatohepatitis.